+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Hyperimmunoglobulin prophylaxis, monitoring and preemptive ganciclovir treatment eliminate the risk of CMV infection to improve patient and renal allograft survival



Hyperimmunoglobulin prophylaxis, monitoring and preemptive ganciclovir treatment eliminate the risk of CMV infection to improve patient and renal allograft survival



Transplant International 13 Suppl 1: S354-S358



This study was designed to investigate whether the introduction of ganciclovir to clinical use for anti-CMV treatment changes the risk of CMV infection in renal transplant patients. A total of 1545 cases who had received cadaveric renal transplants were divided into two groups: group 1 (n = 721) was made up of patients who received their transplants within 6 years before the introduction (1991) of ganciclovir and group 2 (n = 824), of individuals transplanted thereafter. Patient and graft survival of CMV D+/R- patients was uni- and multivariately compared with non-CMV D+/R- patients. In CMV D+/R- patients in group 1, survival was significantly lower, and their relative risk for graft loss was 1.32-fold (P = 0.0483) that of non-CMV D+/R- patients. In group 2 patient and graft survival was identical regardless of whether the patients were at risk for CMV infection or not. The risk of CMV infection can be eliminated by hyperimmunoglobulin prophylaxis, CMV monitoring and preemptive ganciclovir treatment in renal transplant patients.

(PDF emailed within 0-6 h: $19.90)

Accession: 046298492

Download citation: RISBibTeXText

PMID: 11112031

DOI: 10.1007/s001470050360


Related references

Treatment of active CMV infection in renal allograft recipients with oral ganciclovir Monitoring efficacy using quantitative CMV-PCR. Journal of Investigative Medicine 49(1): 48A, January, 2001

Treatment of active CMV infection with oral ganciclovir in renal allograft recipients Monitoring efficacy with quantitative CMV-PCR. Journal of the American Society of Nephrology 11(Program and Abstract Issue): 719A-720A, September, 2000

Impact of ganciclovir prophylaxis on CMV infection in cadaveric renal allograft recipients. Journal of the American Society of Nephrology 5(3): 1032, 1994

Risk factors for cytomegalovirus disease in high risk renal allograft recipients under oral ganciclovir prophylaxis. Nephrology Dialysis Transplantation 16(6): A219, June, 2001

Preemptive oral ganciclovir therapy versus prophylaxis to prevent symptomatic cytomegalovirus infection after kidney transplantation. Transplantation Proceedings 33(7-8): 3621-3623, 2001

Successful use of oral ganciclovir for the treatment of intrauterine cytomegalovirus infection in a renal allograft recipient. Transplant Infectious Disease 7(2): 71-74, 2005

Preemptive treatment with oral ganciclovir for pediatric renal transplantation. Clinical Nephrology 61(4): 246-252, 2004

Cytomegalovirus detection in blood and bronchoalveolar lavage, and prophylaxis or preemptive treatment with ganciclovir in children with allogeneic stem cell transplantation. Enfermedades Infecciosas Y Microbiologia Clinica 24(3): 162-166, 2006

Using HLA antibody detection, monitoring, and treatment to improve long-term allograft survival. Clinical Transplants: 317-322, 2011

Ganciclovir prophylaxis improves late murine cytomegalovirus-induced renal allograft damage. Transplantation 95(1): 48-53, 2013

Prophylaxis of CMV disease by ganciclovir (DHPG) in seronegative recipients of renal allograft from seropositive donors. Transplant International 5 Suppl 1: S30-S31, 1992

Factors for cmv infection in renal transplantation effect of donor cmv ak status and prophylaxis with hyperimmunoglobulin or immunoglobulin on the incidence of infection a prospective randomized trial. Touraine, J L , Et Al (Ed ) Transplantation And Clinical Immunology, Vol Xxiii Virus And Transplantation; Proceedings Of The Twenty-Third International Course, Lyon, France, June 3-5, Xiii+434p Elsevier Science Publishers B V : Amsterdam, Netherlands; (Dist in The Usa And Canada By Elsevier Science Publishing Co , Inc : New York, New York, Usa) Illus 347, 1991

Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease. Revista de Investigacion Clinica; Organo del Hospital de Enfermedades de la Nutricion 54(3): 198-203, 2002

Long-term renal graft function and survival in patients with high-risk for cytomegalovirus infection receiving preemptive therapy. Revista de Investigacion Clinica; Organo del Hospital de Enfermedades de la Nutricion 60(5): 365-374, 2009

A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients. Journal of Infectious Diseases 189(8): 1355-1361, 2004